% | $
Quotes you view appear here for quick access.

Endocyte, Inc. Message Board

  • andras1 andras1 Mar 25, 2014 5:39 AM Flag

    From RBC March 21

    More catalysts remain; shares should continue
    going higher
    Our view: Both catalytic events, EU approval and Phase II NSCLC data,
    worked favorably but there are more derisking and positive events coming
    up in 2014 to take shares higher.
    Key points:
    What matters now is that ECYT’s small molecule drug conjugate
    technology should be considered a platform with two Phase II studies
    having read out positive. While vintafolide is partnered with Merck,
    there are several compounds, including a second-gen vintafolide
    plus one targeting inflammation that remain unpartnered. The EU
    recommendation for approval in PROC brings in commercial revenues in
    2014. ECYT could now also have a take-out potential associated with it
    especially if the ongoing Phase III PROC study is positive and the NSCLC
    program enters Phase III. What we like about ECYT is its technology
    platform, the targeted, identifiable patient population with a companion
    diagnostic, multiple partnered and proprietary programs, and active news
    flow. We continue to recommend ECYT shares at current levels. We are
    raising our price target by increasing the probabilities of success for the
    NSCLC program, raising the eligible population to adeno, and including a
    higher price for the diagnostic.
    Here’s what matters:
    1. EU recommends vintafolide for approval. We had modeled a later
    approval so this brings in revenues starting 2014. We have also raised
    our diagnostic price assumption based on ECYT comments.
    2. Phase II NSCLC data positive; Phase III trial likely. Combination
    vintafolide + docetaxel arm beat docetaxel alone using a one sided
    test with PFS HR 0.75, p-value 0.696 (p-value

4.65-0.16(-3.33%)Nov 27 1:00 PMEST